Nanjing Shenzhou Jiamei Pharmaceutical Co., Ltd.

Primary objective: Compared with Esomeprazole sodium for injection (ESO), different doses of H008 injection were given to patients with upper gastrointestinal bleeding caused by peptic ulcer and high risk of rebleeding after endoscopic treatment to evaluate the preliminary effectiveness of reducing the risk of rebleeding. Secondary objectives: 1) Compared with ESO for injection, different doses of H008 injection were given to patients with upper gastrointestinal bleeding caused by peptic ulcer and high risk of rebleeding after endoscopic treatment to evaluate the preliminary safety of this product; 2) Observe the pharmacokinetic characteristics of different doses of H008 injection in the population with peptic ulcer bleeding, and further evaluate the population pharmacokinetic characteristics of this product in patients.

Primary objective: To evaluate the drug interactions of quadruple therapy of Caprasin hydrochloride tablets (combined with clarithromycin tablets, amoxicillin capsules, and bismuth potassium citrate capsules), and to investigate the pharmacokinetic differences of bismuth potassium citrate capsules in different dosing groups. Secondary objective: To evaluate the safety of quadruple therapy of Caprasin hydrochloride tablets (combined with clarithromycin tablets, amoxicillin capsules, and bismuth potassium citrate capsules) and quadruple therapy of esomeprazole magnesium enteric-coated tablets (combined with clarithromycin tablets, amoxicillin capsules, and bismuth potassium citrate capsules).

Primary purpose: For patients with upper gastrointestinal bleeding caused by acute gastric and/or duodenal ulcer and high risk of rebleeding, the drug is given after endoscopic treatment to evaluate the effectiveness of H009 injection in reducing the risk of rebleeding, which is non-inferior to esomeprazole sodium for injection (ESO); Secondary purpose: 1) Compared with ESO for injection, H009 injection is given after endoscopic treatment to patients with upper gastrointestinal bleeding caused by acute gastric and/or duodenal ulcer and high risk of rebleeding to evaluate the effect on rebleeding-related events; 2) Compared with ESO for injection, observe the safety of H009 injection for upper gastrointestinal bleeding caused by acute gastric and/or duodenal ulcer.